Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.

Neuro-oncology advances·2022
Same author

A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics.

Neuro-oncology·2022
Same author

"You can observe a lot by just watching" (Yogi Berra).

Neuro-oncology·2021
Same author

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.

The Lancet. Oncology·2021
Same author

Leptomeningeal metastases: how best to assess response.

Neuro-oncology·2020

Related Experiment Video

Updated: Mar 20, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

14.1K

Anaplastic astrocytoma.

Sean A Grimm1, Marc C Chamberlain2

  • 1Northwestern Medicine Brain & Spine Tumor Center, Warrenville, IL 60555, USA.

CNS Oncology
|May 28, 2016
PubMed
Summary
This summary is machine-generated.

Anaplastic astrocytoma (AA) classification is evolving beyond histology to include molecular markers like IDH mutation and 1p/19q co-deletion status. These markers significantly impact patient prognosis and treatment strategies for this malignant brain tumor.

Keywords:
WHO grade III gliomaanaplastic astrocytomamalignant glioma

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.9K

Related Experiment Videos

Last Updated: Mar 20, 2026

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

14.1K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K
Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.9K

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Cancer Genomics

Background:

  • Anaplastic astrocytoma (AA) is a malignant primary brain tumor characterized by diffuse infiltration.
  • Current classification relies on histology, but future schemes will integrate molecular alterations.
  • Subgrouping based on 1p/19q co-deletion and IDH mutation status reveals distinct prognoses.

Purpose of the Study:

  • To elucidate the prognostic significance of molecular subgroups in anaplastic astrocytoma.
  • To evaluate the efficacy of treatment strategies based on molecular profiles, particularly in non-codeleted AA.
  • To assess the role of temozolomide (TMZ) chemotherapy in different IDH subgroups.

Main Methods:

  • Classification of AA based on histological and molecular features, including IDH mutation and 1p/19q co-deletion status.
  • Analysis of patient age, median survival, and treatment outcomes across different molecular subgroups.
  • Evaluation of preliminary results from the CATNON clinical trial regarding radiotherapy and TMZ chemotherapy.

Main Results:

  • AA subgroups with 1p/19q co-deletion and IDH mutation exhibit the best prognosis.
  • Intermediate prognosis is observed in AA with IDH mutation but without 1p/19q co-deletion.
  • Wild-type IDH anaplastic astrocytomas have the poorest prognosis and share molecular similarities with glioblastoma.

Conclusions:

  • Molecular profiling, specifically IDH mutation and 1p/19q co-deletion status, is crucial for anaplastic astrocytoma classification and prognosis.
  • Treatment strategies, including maximal safe resection, radiotherapy, and temozolomide chemotherapy, are being refined based on these molecular subgroups.
  • Ongoing and recently completed clinical trials like CATNON are vital for optimizing therapeutic approaches for anaplastic astrocytoma.